The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-08), Natera's share price is $97.22. Natera's Book Value per Share for the quarter that ended in Dec. 2023 was $6.40. Hence, Natera's PB Ratio of today is 15.19.
The historical rank and industry rank for Natera's PB Ratio or its related term are showing as below:
NTRA'
s PB Ratio Range Over the Past 10 Years
Min: 1.9 Med: 11.06 Max: 349.11
Current: 15.18
During the past 11 years, Natera's highest PB Ratio was 349.11. The lowest was 1.90. And the median was 11.06.
NTRA's PB Ratio is ranked worse than 97.1% of 207
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.16
vs NTRA: 15.18
During the past 12 months, Natera's average Book Value Per Share Growth Rate was 0.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 4.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 51.30% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Natera was 136.70% per year. The lowest was -47.90% per year. And the median was 21.00% per year.
Back to Basics: PB Ratio
Natera PB Ratio Historical Data
The historical data trend for Natera's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Natera's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Natera's PB Ratio Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Natera's PB Ratio distribution charts can be found below:
* The bar in red indicates where Natera's PB Ratio falls into.
Natera PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Natera's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Natera PB Ratio Related Terms
Thank you for viewing the detailed overview of Natera's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NTRA has been successfully added to your 